Hao Wei (Linda) Sun

Assistant Professor

Department of Medicine

Division of Hematology (DoM)
    Contact details are for academic matters only.

About Me


Doctor of Medicine, University of Toronto (2009)

Internal Medicine, University of Toronto (2009-2012)

Hematology, University of British Columbia (2012-2014)

Clinician Investigators Program, Masters of Health Sciences (Clinical Epidemiology), University of British Columbia (2014-2017)

Selected publications:

1. Sun H. Chan S, Yenson P, Jackson S. risk stratification and individualized treatment in non-severe hemophilia A patients: A single-institution practice audit. Clin Appl Thromb Hemost. 2018 Jan 1. doi: 10.1177/1076029617737836. [Epub ahead of print]

2. Sun HL, Atenafu EG, Tsang R, Kukreti V, Marras TK, Crump M, Kuruvilla J. Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.Leuk Lymphoma. 2017;58:2607-14. 

3. Sun H, McIntosh KA, Squire SJ, Yang M, Bartholomew C, et al. Patient powered prophylaxis: A 12-month study of individualized prophylaxis in adults with severe haemophilia A. Haemophilia 2017; 23: 877-83. 

4. Sun H, Yang M, Fung M, Chan S, Jawi M, et al. Adult males with haemophilia have a different macrovascular and microvascular endothelial function profile compared with healthy controls.Haemophilia. 2017; 23: 777-83. 

5. Sun HL, McIntosh K, Woo C, Crilly E, Bartholomew C, et al. Prevalence and predictors of loss to follow-up in young adults with mild hemophilia. Haemophilia 2017;23:e36-8.

6. Sun HL, Yang M, Sait AS, von Drygalski A, Jackson S. Hematuria is not a risk factor of hypertension or renal impairment in patients with hemophilia. Haemophilia 2016;22: 549-55. 

7. Gue D, Bartholomew C, McIntosh K, Bartholomew C, Summers N, et al. Joining the patient on the path to customized prophylaxis: One hemophilia team explores the tools of engagement. Journal of Multidisciplinary Healthcare. 2015; 8:527-34.

8. Sun H, Savage KJ, Karsan A, Slack GW, Gascoyne RD, Toze CL, et al.

Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2015;15:341-8.

 9. Sun H, Atenafu EG, Yeboah E, Reece DE, Trudel S, et al. Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia and Lymphoma. 2015;56:407-14.


Hemophilia and other bleeding disorders, hemoglobinopathies, patient reported outcomes, quality improvement


2018-2020       Marshall Eliuk Fund for Clinical Innovation in Hematology

                       Development of a population-based Alberta administrative database in bleeding disorders

2018-2020       Marshall Eliuk Fund for Clinical Innovation in Hematology

                       Multidisciplinary Northern Alberta Transition Clinic for Hemoglobinopathies (MATCH)

2018-2020       2018 Edmonton Zone Quality Improvement competition, Chief Medical Officer of Quality Healthcare Improvement

                       Improving care of Northern Alberta patients with suspected TTP, a quality improvement initiative

2016-2017       Canadian Hemophilia Society (CHS) Care Until Cure Research Program

                       Outcome indicators of transitional care in adolescents with hemophilia